Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

Catia Andreassi, Jill Jarecki, Jianhua Zhou, Daniel D. Coovert, Umrao R. Monani, Xiaocum Chen, Mike Whitney, Brian Pollok, Minlei Zhang, Elliot Androphy, Arthur H M Burghes

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Proximal spinal muscular atrophy (SMA) is a common motor neuron disorder caused by mutation of the telomeric survival of motor neuron gene SMN1. The centromeric survival of motor neuron SMN2 gene is retained in all SMA patients but does not produce sufficient SMN protein to prevent the development of clinical symptoms. The SMN1 and SMN2 genes differ functionally by a single nucleotide change. This change affects the efficiency with which exon 7 is incorporated into the mRNA transcript. Thus, SMN2 produces less full-length mRNA and protein than SMN1. We have screened a library of compounds in order to identify ones that can alter the splicing pattern of the SMN2 gene. Here, we report that the compound aclarubicin increases the retention of exon 7 into the SMN2 transcript. We show that aclarubicin effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34. In type I fibroblasts, treatment resulted in an increase in SMN protein and gems to normal levels. Our results suggest that alteration of splicing pattern represents a new approach to modification of gene expression in disease treatment and demonstrate the feasibility of high throughput screens to detect compounds that affect the splicing pattern of a gene.

Original languageEnglish (US)
Pages (from-to)2841-2849
Number of pages9
JournalHuman Molecular Genetics
Volume10
Issue number24
StatePublished - Nov 15 2001
Externally publishedYes

Fingerprint

Aclarubicin
Spinal Muscular Atrophies of Childhood
Motor Neurons
Genes
Spinal Muscular Atrophy
Exons
Therapeutics
Fibroblasts
Messenger RNA
Proteins
Nucleotides
Gene Expression
Cell Line
Mutation

ASJC Scopus subject areas

  • Genetics

Cite this

Andreassi, C., Jarecki, J., Zhou, J., Coovert, D. D., Monani, U. R., Chen, X., ... Burghes, A. H. M. (2001). Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Human Molecular Genetics, 10(24), 2841-2849.

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. / Andreassi, Catia; Jarecki, Jill; Zhou, Jianhua; Coovert, Daniel D.; Monani, Umrao R.; Chen, Xiaocum; Whitney, Mike; Pollok, Brian; Zhang, Minlei; Androphy, Elliot; Burghes, Arthur H M.

In: Human Molecular Genetics, Vol. 10, No. 24, 15.11.2001, p. 2841-2849.

Research output: Contribution to journalArticle

Andreassi, C, Jarecki, J, Zhou, J, Coovert, DD, Monani, UR, Chen, X, Whitney, M, Pollok, B, Zhang, M, Androphy, E & Burghes, AHM 2001, 'Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients', Human Molecular Genetics, vol. 10, no. 24, pp. 2841-2849.
Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, Chen X et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Human Molecular Genetics. 2001 Nov 15;10(24):2841-2849.
Andreassi, Catia ; Jarecki, Jill ; Zhou, Jianhua ; Coovert, Daniel D. ; Monani, Umrao R. ; Chen, Xiaocum ; Whitney, Mike ; Pollok, Brian ; Zhang, Minlei ; Androphy, Elliot ; Burghes, Arthur H M. / Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. In: Human Molecular Genetics. 2001 ; Vol. 10, No. 24. pp. 2841-2849.
@article{4691f2c6752c4208be5919d2b407c97b,
title = "Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients",
abstract = "Proximal spinal muscular atrophy (SMA) is a common motor neuron disorder caused by mutation of the telomeric survival of motor neuron gene SMN1. The centromeric survival of motor neuron SMN2 gene is retained in all SMA patients but does not produce sufficient SMN protein to prevent the development of clinical symptoms. The SMN1 and SMN2 genes differ functionally by a single nucleotide change. This change affects the efficiency with which exon 7 is incorporated into the mRNA transcript. Thus, SMN2 produces less full-length mRNA and protein than SMN1. We have screened a library of compounds in order to identify ones that can alter the splicing pattern of the SMN2 gene. Here, we report that the compound aclarubicin increases the retention of exon 7 into the SMN2 transcript. We show that aclarubicin effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34. In type I fibroblasts, treatment resulted in an increase in SMN protein and gems to normal levels. Our results suggest that alteration of splicing pattern represents a new approach to modification of gene expression in disease treatment and demonstrate the feasibility of high throughput screens to detect compounds that affect the splicing pattern of a gene.",
author = "Catia Andreassi and Jill Jarecki and Jianhua Zhou and Coovert, {Daniel D.} and Monani, {Umrao R.} and Xiaocum Chen and Mike Whitney and Brian Pollok and Minlei Zhang and Elliot Androphy and Burghes, {Arthur H M}",
year = "2001",
month = "11",
day = "15",
language = "English (US)",
volume = "10",
pages = "2841--2849",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "24",

}

TY - JOUR

T1 - Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

AU - Andreassi, Catia

AU - Jarecki, Jill

AU - Zhou, Jianhua

AU - Coovert, Daniel D.

AU - Monani, Umrao R.

AU - Chen, Xiaocum

AU - Whitney, Mike

AU - Pollok, Brian

AU - Zhang, Minlei

AU - Androphy, Elliot

AU - Burghes, Arthur H M

PY - 2001/11/15

Y1 - 2001/11/15

N2 - Proximal spinal muscular atrophy (SMA) is a common motor neuron disorder caused by mutation of the telomeric survival of motor neuron gene SMN1. The centromeric survival of motor neuron SMN2 gene is retained in all SMA patients but does not produce sufficient SMN protein to prevent the development of clinical symptoms. The SMN1 and SMN2 genes differ functionally by a single nucleotide change. This change affects the efficiency with which exon 7 is incorporated into the mRNA transcript. Thus, SMN2 produces less full-length mRNA and protein than SMN1. We have screened a library of compounds in order to identify ones that can alter the splicing pattern of the SMN2 gene. Here, we report that the compound aclarubicin increases the retention of exon 7 into the SMN2 transcript. We show that aclarubicin effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34. In type I fibroblasts, treatment resulted in an increase in SMN protein and gems to normal levels. Our results suggest that alteration of splicing pattern represents a new approach to modification of gene expression in disease treatment and demonstrate the feasibility of high throughput screens to detect compounds that affect the splicing pattern of a gene.

AB - Proximal spinal muscular atrophy (SMA) is a common motor neuron disorder caused by mutation of the telomeric survival of motor neuron gene SMN1. The centromeric survival of motor neuron SMN2 gene is retained in all SMA patients but does not produce sufficient SMN protein to prevent the development of clinical symptoms. The SMN1 and SMN2 genes differ functionally by a single nucleotide change. This change affects the efficiency with which exon 7 is incorporated into the mRNA transcript. Thus, SMN2 produces less full-length mRNA and protein than SMN1. We have screened a library of compounds in order to identify ones that can alter the splicing pattern of the SMN2 gene. Here, we report that the compound aclarubicin increases the retention of exon 7 into the SMN2 transcript. We show that aclarubicin effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34. In type I fibroblasts, treatment resulted in an increase in SMN protein and gems to normal levels. Our results suggest that alteration of splicing pattern represents a new approach to modification of gene expression in disease treatment and demonstrate the feasibility of high throughput screens to detect compounds that affect the splicing pattern of a gene.

UR - http://www.scopus.com/inward/record.url?scp=0035891862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035891862&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 2841

EP - 2849

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 24

ER -